2806-29-3

Usage

Uses

Used in Pharmaceutical Industry:
2-CHLORO-4-(TRIFLUOROMETHYL)QUINOLINE is used as a building block for the synthesis of pharmaceutical agents and drugs. Its chemical structure and properties enable the development of new compounds with potential therapeutic applications.
Used in Medicinal Chemistry Research:
2-CHLORO-4-(TRIFLUOROMETHYL)QUINOLINE is employed as a valuable tool in medicinal chemistry research, where it aids in the discovery and optimization of new drug candidates with potential biological activity.
Used in Drug Development:
2-CHLORO-4-(TRIFLUOROMETHYL)QUINOLINE is utilized in drug development processes to create novel compounds with potential use in the treatment of various diseases and conditions, contributing to advancements in healthcare and medicine.

Upstream product

• 25199-84-2 2-Hydroxy-4-(trifluormethyl)-chinolin 
• 25199-84-2 4-(trifluoromethyl)quinolin-2(1H)-one 
• 62-53-3 aniline 

Downstream Products

• 1076236-51-5 C₁₀H₈F₃N₃ 
• 25199-77-3 4-(trifluoromethyl)quinoline 
• 25199-89-7 4-trifluoromethyl-quinoline-2-carbonitrile 

Relevant academic research and scientific papers

Substituents engineered deep-red to near-infrared phosphorescence from tris-heteroleptic iridium(iii) complexes for solution processable red-NIR organic light-emitting diodes

Research on near-infrared- (NIR-) emitting materials and devices has been propelled by fundamental and practical application demands surrounding information-secured devices and night-vision displays to phototherapy and civilian medical diagnostics. However, the development of stable, highly efficient, low-cost NIR-emitting luminophores is still a formidable challenge owing to the vulnerability of the small emissive bandgap toward several nonradiative decay pathways, including the overlapping of ground- and excited-state vibrational energies and high-frequency oscillators. Suitable structural designs are mandatory for producing an intense NIR emission. Herein, we developed a series of deep-red to NIR emissive iridium(iii) complexes (Ir1-Ir4) to explore the effects of electron-donating and electron-withdrawing substituents anchored on the quinoline moiety of (benzo[b]thiophen-2-yl)quinoline cyclometalating ligands. These substituents help engineer the emission bandgap systematically from the deep-red to the NIR region while altering the emission efficiencies drastically. Single-crystal X-ray structures authenticated the exact coordination geometry and intermolecular interactions in these new compounds. We also performed an in-depth and comparative photophysical study in the solution, neat powder, doped polymer film, and freeze matrix at 77 K states to investigate the effects of substitution on the excited-state properties. These studies were conducted in conjunction with density functional theory (DFT) and time-dependent density functional theory (TD-DFT) calculations. Most importantly, the -CH3 substituted Ir1, unsubstituted Ir2, and -CF3 substituted complex (Ir4) were promising novel compounds with bright phosphorescence quantum efficiency in doped polymer films. Using these novel molecules, deep-red to NIR emissive organic light-emitting diodes (OLEDs) were fabricated using a solution-processable method. The unoptimized device exhibited maximum external quantum efficiency (EQE) values of 2.05% and 2.11% for Ir1 and Ir2, respectively.

SUBSTITUTED AZOLE DIONE COMPOUNDS WITH ANTIVIRAL ACTIVITY

Provided herein are methods of using substituted azole dione compounds for treatment of viral infections.

σ-Bond Hydroboration of Cyclopropanes

Hydroboration of alkenes is a classical reaction in organic synthesis in which alkenes react with boranes to give alkylboranes with subsequent oxidation resulting in alcohols. The double bond (π-bond) of alkenes can be readily reacted with boranes owing to its high reactivity. However, the single bond (σ-bond) of alkanes has never been reacted. To pursue the development of σ-bond cleavage, we selected cyclopropanes as model substrates since they present a relatively weak σ-bond. Herein, we describe an iridium-catalyzed hydroboration of cyclopropanes, resulting in β-methyl alkylboronates. These unusually branched boronates can be derivatized by oxidation or cross-coupling chemistry, accessing "designer"products that are desired by practitioners of natural product synthesis and medicinal chemistry. Furthermore, mechanistic investigations and theoretical studies revealed the enabling role of the catalyst.

Novel Sulfonaminoquinoline Hepcidin Antagonists

The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

Compounds with anti-cancer activity

Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.

QUINOLINE, TETRAHYDROQUINOLINE AND PYRIMIDINE DERIVATIVES AS MCH ANTAGONIST

The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.